Bristol-Myers Squibb (BMY) Q3 2025 Earnings
Bristol-Myers Squibb reported Q3 2025 revenue of $12.2B (+2.8% YoY), beat analyst consensus of $11.9B by $371.9M. Diluted EPS came in at $1.63 (-9.4% YoY), beat the $1.52 consensus by $0.11. Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals.
Financial Snapshot
Trailing eight quarters through Q3 2025
Q3 2025 Earnings FAQ
Common questions about Bristol-Myers Squibb's Q3 2025 earnings report.
Bristol-Myers Squibb (BMY) reported Q3 2025 earnings on October 30, 2025 before market open.
Bristol-Myers Squibb reported revenue of $12.2B and diluted EPS of $1.63 for Q3 2025.
Revenue beat the consensus estimate of $11.9B by $371.9M. EPS beat the consensus estimate of $1.52 by $0.11.
Compared to the same quarter a year prior, revenue grew 2.8% from $11.9B a year earlier and diluted EPS declined 9.4% from $1.80.
You can read the 10-Q periodic report (0000014272-25-000149) directly on SEC EDGAR. The filing index links above go to sec.gov.